TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on Periodontium

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient over 18 years presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is prescribed.~* At least 18 permanent teeth in the mouth at least 3 teeth with a healthy periodontal status~* Having expressed their written free and informed consent~Exclusion Criteria:~* Hypersensitivity to any of the following components : tocilizumab, saccharose, polysorbate 80, phosphate disodique dodécahydrate, phosphate monosodique dehydrate~* Severe or active infections~* Systemic Pathology affecting the immune system including Sjögren's syndrome~* Surgery in the previous month~* HIV positive~* Alcoholic~* Toxicoman~* Antibiotic treatment in the last 2 months~* Legally protected patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patient with parodontitis (Type: OTHER): Patient with rheumatoid arthritis and pparodontitis.
- Patient without parodontitis (Type: OTHER): Patient with rheumatoid arthritis but periodontally healthy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Exclusive Enteral Nutrition and Corticosteroids Therapy in Crohn's Disease (EENCD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed CD for at least 6 months~* Clinically active disease (CDAI \>220 or Harvey-Bradshaw Index (HBI) \>6) or active by endoscopy.~* Biochemical evidence of disease activity (CRP \>5 and/or fecal calprotectin \>250)~Exclusion Criteria:~* Currently using EEN~* Condition that would preclude the use of EEN, such as Intestinal obstruction, perforation, toxic megacolon, massive gastrointestinal bleeding, abdominal abscess, or stricturing disease~* Previous intestinal resection with a remnant bowel of less than 180 cm~* Treatment with Prednisone in the last 30 days~* New start or change in dose of azathioprine, 6-mercaptopurine, cyclosporine, other immunosuppressant or biologics in the last 90 days. Doses of these medications must also remain unchanged for the duration of the study~* New start or change in dose of 5-aminosalicylic acid (ASA) in the last 30 days. 5ASA dose must remain unchanged for the duration of the study~* Use of Antibiotics or Probiotics in the last 30 days~* Pregnant or Lactating~* Any serious illness which could interfere with study procedures or results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Standard course CS with Regular Food (Type: ACTIVE_COMPARATOR): 40 mg a day of oral Prednisone for 2 weeks with subsequent taper of daily dose by 5 mg per week.
- Standard course CS with EEN (Type: EXPERIMENTAL): 40 mg a day of oral Prednisone for 2 weeks and taper of daily dose by 5 mg per week and Exclusive Enteral Nutrition for 6 weeks.
- Short course CS with EEN (Type: EXPERIMENTAL): 40 mg a day of oral Prednisone for 3 days and taper of daily dose by 5 mg every 3 days and Exclusive Enteral Nutrition for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have Type 2 Diabetes Mellitus~* 18 to 65 years of age~Exclusion Criteria:~* History of Type 1 Diabetes or ketoacidosis~* Have been treated with lipid lowering medications 4 weeks before starting the study~* Have started on a weight loss program and not in the maintenance phase or have started weight loss medication within the last 12 weeks~* Have had surgery in the last 30 days~* History of active liver disease~* History of coronary heart disease or congestive heart failure~* Have had a stroke or transient ischemic neurological disorder in the past 6 months~* Are Human Immunodeficiency Virus (HIV) Positive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MK8245 5 mg b.i.d. (Type: EXPERIMENTAL): MK8245
- MK8245 50 mg b.i.d. (Type: EXPERIMENTAL): MK8245
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pregnancy~* Immigration from a country/geographic area with declared endemic schistosomiasis according to World Health Organization criteria~* Signed informed consent~Exclusion Criteria:~* Placenta pathology of any cause~* Any medical condition affecting fetal growth

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intra-Operative Corticosteroid Injection During Arthroscopic Shoulder Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years-old or older~* Male patients~* Female patients~* Patients able to speak and understand written English~* Patients presenting to the orthopedic institute clinic with shoulder pain and necessitating the procedure of arthroscopic shoulder surgery~* Specific arthroscopic procedures include: intra-articular debridement, decompression, acromioplasty, and acromioclavicular joint resection~Exclusion Criteria:~* Patients undergoing arthroscopic shoulder surgery that includes other interventions (i.e. rotator cuff repair; labral repair, etc)~* Patients with adhesive capsulitis~* Patients with significant cervical spine symptoms and/or pathology~* Patients having a history of receiving chronic pain treatment~* Patients who are currently pregnant or who become pregnant before surgery~* Patients who cannot speak or understand written english~* Patients who are under the age of 18 years of age~* As per exclusionary criteria if a subject is pregnant they will not be eligible for participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A (Type: PLACEBO_COMPARATOR): After arthroscopic surgery the control group (Group A) will undergo a subacromial marcaine injection (standard of care).
- Group B (Type: EXPERIMENTAL): After arthroscopic surgery the experimental group (Group B) will undergo a subacromial corticosteroid injection+marcaine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of the Effect of Intravenous Galactose on Diabetic Macular Oedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 1 or type 2 diabetes~* clinically significant macular oedema~* visual acuity of minimum 40 letters by the ETDRS procedure~* retinal thickness of at least 250 microns in the foveal region on three retinal maps of the fast protocol of the StratusOCT at baseline or at least 300 microns outside the foveal region~* 1 disc area of oedema within 3000 microns from the foveal center on three retinal maps of the fast protocol of the StratusOCT at baseline~* maximal blood pressure 160/90 mmHg (mean of three measurements)~* informed consent~Exclusion Criteria:~* other ocular diseases or treatments, that can cause or influence the macular oedema, including prior laser photocoagulation. Traction oedema is allowed.~* glaucoma~* media opacities that significantly impairs the light reflection while scanning~* Pregnancy~* severe heart, lung and/or renal insufficiency (judged by the primary investigator)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed AML other than acute promyelocytic leukemia (APL) according to WHO criteria~* In AML defined by cytogenetic aberrations the proportion of blasts may be \<20%~* Age ≥60 years~* Clinical performance corresponding to ECOG score 0-2~* High-risk karyotype~* \<5% myeloblasts in bone marrow ≥21 days after beginning of most recent chemotherapy~* maximal two preceding chemotherapy cycles~* Potentially available haploidentical family donor (child/ sibling), willing and fit for NK cell donation~Exclusion Criteria:~* AML with favorable or intermediate risk cytogenetic features~* Persistent aplasia following preceding chemotherapy~* Relapsed or refractory AML~* Known pre-existing autoimmune diseases~* Any severe concomitant condition which makes it undesirable for the patient to participate in the study~* Any condition which could jeorpadize compliance of the protocol~* Participation in another clinical trial during or within 4 weeks before study entry

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- NK cells (Type: EXPERIMENTAL): Infusion of haploidentical NK cells after immunosuppression with cyclophosphamide and fludarabine, followed by immunostimulatory treatment with interleukin-2
- Control Intervention (Type: ACTIVE_COMPARATOR): 1 cycle of consolidation chemotherapy with high-dose cytarabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: AZD7325 Japan Multiple Ascending Dose (MAD) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese subjects~Exclusion Criteria:~* Significant illness, as judged by the investigator, within 2 weeks of Day 1~* Enrollment in another concurrent investigational study or intake of an investigational drug within 4 months prior to the screening visit~* Blood loss in excess of 200 mL within 30 days of Day 1, in excess of 400 mL within 90 days of Day 1, or in excess of 1200 mL within 1 year of Day 1~* Clinically relevant abnormalities in physical examinations, vital signs, clinical chemistry, hematology or urinalysis as judged by the investigator and/or sponsor

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Low dose or placebo, twice daily
- 2 (Type: EXPERIMENTAL): Low dose or placebo, once daily
- 3 (Type: EXPERIMENTAL): Middle dose or placebo, twice daily
- 4 (Type: EXPERIMENTAL): High dose or placebo, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Optimum Radiographic Assessment of the Knee

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Knee osteoarthritis any grade, affecting the tibio-femoral joint~* Participant is willing and able to give informed consent for participation in the study.~* Male or Female, aged 50 years or above.~* In the Investigator's opinion, is able and willing to comply with all trial requirements.~* Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the trial.~Exclusion Criteria:~* Previous joint replacement on ipsilateral knee~* Previous anterior cruciate ligament reconstruction or injury~* Previous high tibial osteotomy~* Previous intraarticular fracture~* History of Inflammatory arthritis~* Unable to stand with assistance for two minutes

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Valgus stress - lateral compartment (Type: EXPERIMENTAL): Valgus stress radiograph. Joint space width measured in lateral compartment.
- Varus stress - medial compartment (Type: EXPERIMENTAL): Varus stress radiograph. Joint space width measured in medial compartment.
- 0 degree flexion - medial compartment (Type: EXPERIMENTAL): 0 degree flexion radiograph. Joint space width measured in medial compartment.
- 0 degree flexion - lateral compartment (Type: EXPERIMENTAL): 0 degree flexion radiograph. Joint space width measured in medial compartment.
- 20 degree flexion - medial compartment (Type: EXPERIMENTAL): 20 degree flexion radiograph. Joint space width measured in medial compartment.
- 20 degree flexion - lateral compartment (Type: EXPERIMENTAL): 20 degree flexion radiograph. Joint space width measured in lateral compartment.
- 45 degree flexion - medial compartment (Type: EXPERIMENTAL): 45 degree flexion radiograph. Joint space width measured in medial compartment.
- 45 degree flexion - lateral compartment (Type: EXPERIMENTAL): 45 degree flexion radiograph. Joint space width measured in lateral compartment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Suprapubic Aspiration Versus Urinary Catheterization In Neonates.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria (to be approached for consent):~-All infants who are admitted to the NICU and are not known to have the exclusion criteria listed below at the time of admission~Exclusion criteria (to be approached for consent):~* Antenatal detection or suspicion of genitourinary anomaly including: ambiguous genitalia, hypospadias, posterior urethral valve, anal atresia, exstrophy-epispadias complex, and oligohydramnios secondary to probable genitourinary anomaly(e.g. renal agenesis, multicystic kidney disease)~* Antenatal hydrops~* Antenatally detected abdominal wall defect or abdominal masses~* Antenatally detected grossly dilated bowel loops~* Congenital abdominal skin lesion over the SPA puncture site~Inclusion criteria (prior to randomization):~-All infants who are greater than 72 hours of age, who are being investigated for a possible UTI, and have been consented will be eligible for randomization~Exclusion criteria (prior to randomization):~* Oliguria (\<0.5 cc/kg/hr) or anuria over the 8 hours prior to attempted urine collection~* Skin infection over the SPA puncture site~* Distension or enlargement of abdominal viscera (e.g. grossly dilated loops of bowel or massive organomegaly)~* Active Necrotizing enterocolitis (Bell stage II or more)~* Uncorrected thrombocytopenia (platelets \< 50 x 10 6) or bleeding diathesis~* Post-abdominal surgery~* Large inguinal hernia~* Current pre-existing indwelling catheter

- Gender: ALL
- Minimum Age: 72 Hours
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Suprapubic Aspiration (Type: ACTIVE_COMPARATOR): A trained physician or neonatal nurse practitioner utilizing U/S guidance at the bedside will perform the SPA. An U/S machine is readily available for use in each NICU.
- Urinary Catheterization (Type: ACTIVE_COMPARATOR): The infants will have the procedure done by NICU nurses who have been trained in performing this procedure.~If the randomly assigned infant passes urine spontaneously during a UC attempt after complete perineal cleansing and the urine is collected as a clean catch sample, then this infant will be analysed in the assigned group (intention to treat).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Complaint of dry mouth with ALL the following characteristics: At least 1 week in duration Attributed by the treating physician to an opioid Severity rating at least 20 mm on a 100 mm visual analog scale Must be receiving routine (i.e., not just as needed) dosing with one of the following opioids: morphine, hydromorphone, transdermal fentanyl, methadone, or oxycodone Intent to continue opioid therapy at the same or higher dose over the first 2 weeks that the patient is receiving protocol treatment~PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-3 Life expectancy: At least 6 weeks Hematopoietic: Not specified Hepatic: Not specified Renal: Calcium less than 29.9 mg/dL Cardiovascular: No symptomatic congestive heart failure or hypotension (systolic blood pressure less than 100 mm Hg) Pulmonary: No obstructive pulmonary disease (asthma, chronic bronchitis, or chronic obstructive pulmonary disease) Other: No known sensitivity to pilocarpine No active oral candidiasis No Sjogren's syndrome No acute iritis or narrow-angle glaucoma Not pregnant or nursing Effective contraception required of all fertile patients Must be fluent and possess sufficient cognitive ability to complete quality of life questionnaires in either English or French without assistance from a caregiver~PRIOR CONCURRENT THERAPY: See Disease Characteristics Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to a field encompassing the parotid glands At least 1 week since prior radiotherapy to the chief site of pain No concurrent radiotherapy to chief site of pain for 2 weeks following randomization Surgery: Not specified Other: No concurrent tricyclic antidepressants (amitriptyline, nortriptyline, desipramine, or imipramine)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Pilocarpine (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Salvianolic Acid on AIS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute ischemic stroke with the first onset, or a history of cerebral infarction but with a modified Rankin Scale (mRS) score ≤1, onset within 72h;~2. CT examination to rule out cerebral hemorrhage;~3. With clear signs of nervous system positioning, the National Institutes of Health Stroke Scale (NIHSS) score ≥ 4~Exclusion Criteria:~1. Diseases with bleeding tendency;~2. Liver and kidney dysfunction;~3. Malignant tumors or those undergoing anti-tumor treatment;~4. Allergic physique, allergic to aspirin or Salvianolic Acid;~5. Heart failure, multiple system failure;~6. Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- salvianolic acid group (Type: ACTIVE_COMPARATOR): salvianolic acid group 100mg+0.9%NaCl 250ml, injection, 14 days
- 0.9% NaCl (Type: PLACEBO_COMPARATOR): 0.9%NaCl 250ml, injection, 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility